Evaluation of the effect of atorvastatin on preventing restenosis after vertebral artery stenting with color Doppler flow imaging
10.3969/j.issn.1672-5921.2010.09.001
- Author:
Ling-Yun JIA
1
Author Information
1. Department of Vascular Ultrasound
- Publication Type:Journal Article
- Keywords:
Angioplasty;
Atorvastatin;
Restenosis;
Stents;
Ultrasonograph, Doppler, color;
Vertebrobasilar insufficiency
- From:
Chinese Journal of Cerebrovascular Diseases
2010;7(9):449-453
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the effect of atorvastatin on the prevention of restenosis after vertebral artery origin stenting with color Doppler flow imaging (CDFI). Methods: A total of 59 patients with complete clinical data underwent unilateral vertebral artery origin stenting were recruited in the study. The patients were divided into drug (n =29) and non-drug (n =30) groups according to whether they took atorvastatin (20 mg/d) or not. All the patients were detected by CDFI before and at 1, 6, and 12 months after stenting. The peak systolic velocity (PSV) at the proximal (PSVOS) and intervertebral segments of vertebral artery (PSVIV) were recorded and the ratio of PSVOS/PSVIV was calculated. Digital subtraction angiography (DSA) showed that the in-stent stenosis rate ≥50% was determined as postoperative restenosis. The incidence of restenosis and hemodynamic changes were compared between the two groups. Results: Circled digit oneThe restenosis rates of the drug and non-drug groups at 6 months after stenting were 20.7% (6/29) and 36.7% (11/30) respectively (P >0.05); the restenosis rate (50.0%) of the non-drug group(50%) was significantly higher than that of the drug group (20.7%) at 12 months after stenting (P < 0.05). Circled digit twoThe PSV OS and PSVOS/PSVIV of the patients in both groups at 1 month after stenting were improved more significantly than those before the procedure. PSVOS(187±18 cm/s, 179±20 cm/s) and PSVOS/PSVIV(3.93±0.59, 3.24±0.48) were relatively increased in the non-drug group at 6 months after the procedure, but there was no significant difference. PSVOS (209±21 cm/s, 159±16cm/s) and PSVOS/PSVIV (4.34±0.65, 2.86±0.36) in the non-drug group at 12 months after stenting were significantly higher than those in the drug group. There was significant difference between the two groups (P < 0.05). Conclusions: Atorvastatin can decrease the restenosis rate after vertebral artery stenting. With the prolonged time of drug treatment, it may affect the hemodynamic changes in the abnormal vessels.
